Skip to content
Peptigraph home

Abaloparatide vs Teriparatide: What the Research Shows

Abaloparatide and Teriparatide side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
[class][status]AbaloparatideParathyroid hormone-related peptide analog sold as Tymlos; the label states it reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.[3]
[class][status]TeriparatideParathyroid hormone analog sold as Forteo; the label states it reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.[4]
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Abaloparatide if…

  • you want an FDA-approved product: Tymlos (abaloparatide) is indicated for postmenopausal women with osteoporosis at high risk for fracture[3]

Consider Teriparatide if…

  • you want an FDA-approved product: Forteo (teriparatide) is indicated for postmenopausal women with osteoporosis at high risk for fracture[4]
  • you want the label that also covers glucocorticoid-induced osteoporosis: Forteo is indicated for men and women with osteoporosis associated with sustained systemic glucocorticoid therapy[4]

What they have in common

  • In the ACTIVE trial, hypercalcemia occurred in 3.4% with abaloparatide vs 6.4% with teriparatide[2]
Neither is FDA approved for any use in people. Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 1 of 8 fields where the two differ. Class, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength, Typical study doses are the same or both unknown.

FieldAbaloparatideTeriparatide
Also calledTymlos—

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

What the ACTIVE trial can and cannot say about the two

ACTIVE randomised postmenopausal women to daily injections of placebo, abaloparatide or open-label teriparatide. The comparison with teriparatide was a safety endpoint (hypercalcemia), not a fracture comparison.[2]

The authors write that further research is needed on the efficacy of abaloparatide versus other osteoporosis treatments.[2]

In ACTIVE, placebo and abaloparatide were blinded while teriparatide was open-label; the arms were 821 on placebo, 824 on abaloparatide 80 μg and 818 on teriparatide 20 μg for 18 months.[2]

Label differences that are not in the trial

The Tymlos label gives its recommended dosage as 80 mcg administered subcutaneously once daily.[3]

The Forteo label gives its recommended dosage as 20 mcg per dose, subcutaneously once a day.[4]

The Forteo pen is a single-patient-use prefilled device intended to deliver 28 daily doses of 20 mcg.[4]

The Tymlos prefilled pen delivers 30 doses of 80 mcg each.[3]

The Forteo label says use for more than 2 years during a patient's lifetime should only be considered if the patient remains at or has returned to high fracture risk.[4]

The Forteo label says to administer the first doses where the patient can sit or lie down in case symptoms of orthostatic hypotension occur.[3]

Forteo's label says to store it under refrigeration at all times except when administering.[4]

The label says the serum half-life of teriparatide was approximately 1 hour after subcutaneous injection.[4]

Common questions

Tymlos vs teriparatide: which has fewer side effects?

In ACTIVE, hypercalcemia was less frequent with abaloparatide than with teriparatide, though teriparatide was open-label.[2]

Is Forteo the same as teriparatide?

Forteo is the brand label for teriparatide, and its label dose is 20 mcg once a day.[4]

Can men use Tymlos or Forteo?

Both labels cover men with osteoporosis at high fracture risk, Tymlos to increase bone density and Forteo to increase bone mass.[4]

Sources

  1. 1PubMed search: (abaloparatide[tiab] OR Tymlos[tiab]) AND (teriparatide[tiab] OR Forteo[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.JAMA · 2016PMID 27533157Accessed 2 Oct 2026
  3. 3TYMLOS prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4FORTEO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.